Our house believes that: The clipped lymph node is the true sentinel node after neoadjuvant chemotherapy in N+ patients
Benigno Acea-Nebril,
Alejandra García-Novoa,
Alberto Bouzón Alejandro,
Carlota Díaz Carballada,
Carmen Conde Iglesias
Affiliations
Benigno Acea-Nebril
General Surgey Department, Breast Unit, University Hospital of A Coruña, Spain
Alejandra García-Novoa
General Surgey Department, Breast Unit, University Hospital of A Coruña, Spain; Corresponding author. Calle Atocha Baja 3, 6°B, A Coruña, 15001, Spain.
Alberto Bouzón Alejandro
General Surgey Department, Breast Unit, University Hospital of A Coruña, Spain
Carlota Díaz Carballada
Ginecology Department, Breast Unit, University Hospital of A Coruña, Spain
Carmen Conde Iglesias
Ginecology Department, Breast Unit, University Hospital of A Coruña, Spain
Axillary staging is an important prognostic factor in breast cancer, being sentinel lymph node biopsy (SLNB) the gold standard staging method in early stages. However, in clinically node positive (cN+) patients who converted to clinically node-negative (cN0) after primary systemic therapy (PST) the axillary staging method during surgery remains controversial. There are at least three validated methods: SLNB, targeted axillary dissection (TAD) and marking axillary nodes with radioactive iodine seeds (MARI) procedure. Our house believe that the biopsied and clipped lymph node could predict response to systemic treatment.
